Hospital Pharmacy - March 2013 - (Page 231)

Hosp Pharm 2013;48(3):231–240 2013 Ó Thomas Land Publishers, Inc. www.thomasland.com doi: 10.1310/hpj4803-231 Formulary Drug Reviews Teriflunomide Dennis J. Cada, PharmD, FASHP, FASCP (Editor)p; Kendra Demaris, PharmD†; Terri L. Levien, PharmD‡; and Danial E. Baker, PharmD, FASHP, FASCPx Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2013 monograph topics are apixaban, bedaquiline, raxibacumab, teduglutide, and loxapine inhalation. The DUE/MUE is on apixaban. Generic Name: TERIFLUNOMIDE Proprietary Name: Aubagio (sanoﬁ-aventis) Approval Rating: 1S Therapeutic Class: Immunomodulators, Dihydroorotate Dehydrogenase Inhibitors Similar Drugs: Leﬂunomide Sound- or LookAlike Names: Leﬂunomide INDICATIONS Teriﬂunomide is approved for the treatment of relapsing forms of multiple sclerosis (MS).1 Current therapies for relapsing MS include ﬁngolimod, glatiramer acetate, interferon beta-1a, interferon beta1b, mitoxantrone, and natalizumab.2-4 Table 1 lists the US Food and Drug Administration (FDA)-approved therapies for relapsing MS by mechanism of action and pharmacologic class. Additionally, rituximab is used off-label for the treatment of relapsing remitting MS.3 MS is one of the most common acquired inﬂammatory demyelinating neurological diseases of the central nervous system (CNS) in young adults. It is a chronic, progressive, degenerative neurological disease that presents with demyelination and axonal damage within the CNS. It is more prevalent in women and White patients of northern European descent.5,6 The disease can manifest a variety of neurologic symptoms, including cognitive impairment, incontinence, visual disturbances, and impaired movement. The exact cause of MS is unknown, but it is thought to be caused by the response from the cellular and humoral arms of the immune system combined with environmental triggers and genetic susceptibility. When the peripherally activated myelin-speciﬁc T cells gain access to the CNS, they are able to disrupt the myelin because of the changes created in the blood-brain barrier by various inﬂammatory mediators and other factors. This process results in the release of antigens speciﬁc to the CNS, development of myelin *Executive Editor, The Formulary; †Clinical Instructor, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; ‡Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University, Spokane, Washington; xDirector, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495. The authors indicate no relationships that could be perceived as a conﬂict of interest. Hospital Pharmacy 231 http://www.thomasland.com

Table of Contents for the Digital Edition of Hospital Pharmacy - March 2013

Hospital Pharmacy - March 2013
Editorial
ISMP Medication Error Report Analysis
ISMP Adverse Drug Reactions
Cancer Chemotherapy Update
Off-Label Drug Uses
RxLegal
Integrating Precepting Into Your Daily Practice
Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device
Comparison of the Efficacy and Safety of Two Different Insulin Infusion Protocols in the Medical Intensive Care Unit
Publication Rates of Abstracts Presented at Five National Pharmacy Association Meetings
Case Report: Dabigatran-Associated Gynecologic Bleeding
Formulary Drug Reviews
Continuing Education Case Study Quiz (0.15 CEU)
Current FDA-Related Drug Information
Director’s Forum
Pharmacy Automation and Technology
Index to Advertisers

Hospital Pharmacy - March 2013